We use cookies for a better user experience. Read our Privacy Policy

I Agree

Cryptococcosis Market

Cryptococcosis Market (Treatment - Amphotericin B (Amphocin and Fungizone), Flucytosine (Ancobon), Fluconazole (Diflucan), Voriconazole and Surgery Treatment; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Store, and Mail Order Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

  • According to Transparency Market Research’s latest report on the global cryptococcosis market for the historical period 2017–2018 and forecast period 2019–2027, rise in reported cases of cryptococcosis, surge in number of surgical procedures; overuse of antibiotics, and introduction of new therapies are projected to drive the global cryptococcosis market
  • According to the report, the global cryptococcosis market was valued at US$ 4.7 Bn in 2018 and is anticipated to expand at a CAGR of 4.3% from 2019 to 2027
fa global cryptococcosis market

To know the scope of our report Get a Sample on Cryptococcosis Market

Increase in Reported Cases of Cryptococcosis: A Key Driver

  • HIV positive patients are found to be more prevalent for fungal infection. Around 220,000 cases of cryptococcal meningitis are evident to occur among people with HIV/AIDS worldwide each year, resulting in nearly 181,000 deaths. Most cryptococcal meningitis cases occur in sub-Saharan Africa.
  • According to the Centers for Disease Control and Prevention (CDC) of the U.S., the overall incidence of cryptococcosis was 0.4 to 1.3 cases per 100,000 population and annual incidence among persons with AIDS was between 2 and 7 cases per 1,000; the case-fatality ratio was approximately 12%.
  • Prevalence of cryptococosis lied majorly in Sub-Saharan countries. However, in recent years, many cases of HIV related cryptococcosis occurred in developed countries such as Australia, U.S. and Germany. The advanced screening processes available in these nations also improve the rate of diagnosis, thereby driving the Cryptococcosis drugs industry. Increased HIV related cryptococcosis infection along with rising initiatives by government and non-government organizations for awareness of available treatment is the major factor that drives the growth of cryptococcosis market.

Get a glimpse of the in-depth analysis through our Report Brochure

Improved access to diagnostic facilities to Augment Global Market

  • Accurate diagnosis of cryptococcosis infection is challenging because of lack of technologies to distinguish C. neoformans and C. gattii infections
  • Currently available diagnostic technologies require use of examination of DNA or isolation of the fungus using customized culture media. These technologies are time consuming, expensive, and require skilled operators.
  • However, new technologies such as biomarker detection in blood using immunoassay platforms are being introduced in the market that offer more efficient results. These new technologies are expected to improve diagnosis of cryptococcosis infection. This in turn is likely to drive the cryptococcosis market.

Patent expiry of key drugs and entry of generics to Hamper Global Cryptococcosis Market

  • The Cryptococcosis market experienced a patent cliff during the last decade. Expiration of patents affects the revenue of pharmaceutical companies. Moreover, generic version of a drug hampers the revenue of branded drug products.
  • This factor is expected to have a profound impact on the cryptococcosis drugs market, causing a decline in market revenue. Moreover, approved ANDAs for most of these molecules will lead to intense generic competition. Increasing number of generic drugs and patent expirations will negatively affect the market. Hence, patent expirations are likely to restrain the Cryptococcosis market.

North America to Account for Major Share of Global Cryptococcosis Market

  • North America leads the global cryptococcosis market commanding more than 40% share in the global cryptococcosis market. Recent advances in cryptococcosis diagnostics with biomarker test, reimbursement for disease screening, and improved access to antifungal drugs such as flucytosine are the major drivers of the cryptococcosis market in North America. U.S. is the major market in North America. The cryptococcosis market in the U.S. is driven by rising prevalence of cryptococcus gattii in the Pacific Northwest Region of the U.S. Moreover, major factors such as HIV population, highly structured health care industry, and availability of well-defined reimbursement policies from public and private health insurance firms fuel the growth of the cryptococcosis market in the U.S.
  • Middle East & Africa is the second leading market due to the major contribution of Sub-Saharan countries where the burden of HIV related cryptococcosis infections are very high. Most of the drugs in the region are distributed by non-government organizations. However, the retail pharmacies segment held significant market share in Middle East & Africa.

Expanding operations in future? To get the perfect launch ask for a custom report 

Global Cryptococcosis Market: Competitive Landscape

  • This report profiles major players in the global cryptococcosis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • Key players operating in the global cryptococcosis market include
    • Bristol-Myers Squibb Company
    • Janssen Biotech, Inc. (Johnson & Johnson)
    • Abbott Laboratories
    • Novartis AG
    • Pfizer, Inc.
    • Valeant Pharmaceuticals, Inc.
    • Glenmark Pharmaceuticals
    • Sigmapharm Laboratories LLC.

Global Cryptococcosis Market: Key Developments

Key players in the global cryptococcosis market have adopted strategies such as regulatory approvals, advanced product development, launch of new products, increase in investments and funds, and acquisition & collaborative agreements with other companies. These strategies of key players are likely to fuel the growth of the global cryptococcosis market. A few strategies adopted by players operating in the global cryptococcosis market are:

  • In June 2016, F2G Ltd. Antifungal biotech firm which is backed by Novartis and Novo-nordisk announced the raise of fund for US$ 60 Million.
  • In June 2016, Viamet Pharmaceuticals, Inc.  announced Fast Track Designation approval from the U.S. FDA for it’s VT-1129 drug candidate for the treatment of cryptococcal meningitis

The report on the global cryptococcosis market discusses individual strategies followed by company profiles of manufacturers of cryptococcosis treatment products. The competitive landscape section has been included in the cryptococcosis market report to provide readers with a dashboard view and a company market share analysis of key players operating in the global cryptococcosis market.

Global Cryptococcosis Market – Segmentation

Treatment

Amphotericin B

  • Amphocin
  • Fungizone
  • Other

Flucytosine

  • Ancobon
  • Other

Fluconazole

  • Diflucan
  • Other

Others (Voriconazole, Surgery Treatment, etc.)

Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Drug Store

Mail Order Pharmacies

Others

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Cryptococcosis Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of cryptococcosis market?

The global cryptococcosis market was worth US$ 4.7 Bn and is projected to reach a value of US$ 7.0 Bn by the end of 2027

What is the anticipated CAGR of the cryptococcosis market in forecast period?

Cryptococcosis market is anticipated to grow at a CAGR of 4.3% during the forecast period

Which region is expected to project the highest market share in cryptococcosis market?

North America accounted for a major share of the global cryptococcosis market

What are the key driving factors for the growth of cryptococcosis market?

Cryptococcosis market is driven by rise in reported cases of cryptococcosis, surge in number of surgical procedures; overuse of antibiotics, and introduction of new therapies are projected to drive the global market

Who are the key players in the global cryptococcosis market?

Key players in the global cryptococcosis market include Bristol-Myers Squibb Company, Janssen Biotech, Inc. (Johnson & Johnson), Abbott Laboratories, Novartis AG, Pfizer, Inc., Valeant Pharmaceuticals, Inc., Glenmark Pharmaceuticals and Sigmapharm Laboratories LLC

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cryptococcosis Market

4. Market Overview

    4.1. Introduction

        4.1.1. Treatment Type Definition

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Cryptococcosis Market Analysis and Forecast, 2017–2027

        4.4.1. Market Revenue Projections (US$ Mn)

    4.5. Porter’s Five Force Analysis

5. Market Outlook

    5.1. Disease Prevalence & Incidence Rate globally with key countries / Region

    5.2. Pipeline Analysis

    5.3. Key Industry Developments

6. Global Cryptococcosis Market Analysis and Forecast, by Treatment Type 

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Treatment Type, 2017–2027

        6.3.1. Amphotericin B 

            6.3.1.1. Amphocin 

            6.3.1.2. Fungizone

            6.3.1.3. Other

        6.3.2. Flucytosine 

            6.3.2.1. Ancobon 

            6.3.2.2. Other

        6.3.3. Fluconazole

            6.3.3.1. Diflucan

            6.3.3.2. Other

        6.3.4. Others (Voriconazole, Surgery Treatment, etc.)

    6.4. Market Attractiveness, by Treatment Type 

7. Global Cryptococcosis Market Analysis and Forecast, by Distribution Channel 

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Distribution Channel, 2017–2027

        7.3.1. Hospital Pharmacies

        7.3.2. Retail Pharmacies

        7.3.3. Drug Store

        7.3.4. Mail Order Pharmacies

        7.3.5. Others

    7.4. Market Attractiveness Analysis, by Distribution Channel 

8. Global Cryptococcosis Market Analysis and Forecast, by Region

    8.1. Key Findings

    8.2. Market Value Forecast, by Region

        8.2.1. North America 

        8.2.2. Europe 

        8.2.3. Asia Pacific 

        8.2.4. Latin America 

        8.2.5. Middle East & Africa 

    8.3. Market Attractiveness Analysis, by Region

9. North America Cryptococcosis Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast By Treatment Type, 2017–2027

        9.2.1. Amphotericin B 

            9.2.1.1. Amphocin 

            9.2.1.2. Fungizone

            9.2.1.3. Other

        9.2.2. Flucytosine 

            9.2.2.1. Ancobon 

            9.2.2.2. Other

        9.2.3. Fluconazole

            9.2.3.1. Diflucan

            9.2.3.2. Other

        9.2.4. Others (Voriconazole, Surgery Treatment, etc.)

    9.3. Market Value Forecast, by Distribution Channel, 2017–2027

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Drug Store

        9.3.4. Mail Order Pharmacies

        9.3.5. Others

    9.4. Market Value Forecast, by Country, 2017–2027

        9.4.1. U.S.

        9.4.2. Canada

    9.5. Market Attractiveness Analysis 

        9.5.1. By Treatment Type 

        9.5.2. By Distribution Channel 

        9.5.3. By Country

10. Europe Cryptococcosis Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Treatment Type, 2017–2027

        10.2.1. Amphotericin B 

            10.2.1.1. Amphocin 

            10.2.1.2. Fungizone

            10.2.1.3. Other

        10.2.2. Flucytosine 

            10.2.2.1. Ancobon 

            10.2.2.2. Other

        10.2.3. Fluconazole

            10.2.3.1. Diflucan

            10.2.3.2. Other

        10.2.4. Others (Voriconazole, Surgery Treatment, etc.)

    10.3. Market Value Forecast, by Distribution Channel, 2017–2027

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Drug Store

        10.3.4. Mail Order Pharmacies

        10.3.5. Others

    10.4. Market Value Forecast, by Country/Sub-region, 2017–2027

        10.4.1. Germany

        10.4.2. U.K.

        10.4.3. France

        10.4.4. Spain

        10.4.5. Italy

        10.4.6. Rest of Europe

    10.5. Market Attractiveness Analysis 

        10.5.1. By Treatment Type 

        10.5.2. By Distribution Channel 

        10.5.3. By Country/Sub-region

11. Asia Pacific Cryptococcosis Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Treatment Type, 2017–2027

        11.2.1. Amphotericin B 

            11.2.1.1. Amphocin 

            11.2.1.2. Fungizone

            11.2.1.3. Other

        11.2.2. Flucytosine 

            11.2.2.1. Ancobon 

            11.2.2.2. Other

        11.2.3. Fluconazole

            11.2.3.1. Diflucan

            11.2.3.2. Other

        11.2.4. Others (Voriconazole, Surgery Treatment, etc.)

    11.3. Market Value Forecast, by Distribution Channel, 2017–2027

        11.3.1. Hospital Pharmacies

        11.3.2. Retail Pharmacies

        11.3.3. Drug Store

        11.3.4. Mail Order Pharmacies

        11.3.5. Others

    11.4. Market Value Forecast, by Country/Sub-region, 2017–2027

        11.4.1. China

        11.4.2. Japan

        11.4.3. India

        11.4.4. Australia & New Zealand

        11.4.5. Rest of Asia Pacific

    11.5. Market Attractiveness Analysis 

        11.5.1. By Treatment Type 

        11.5.2. By Distribution Channel 

        11.5.3. By Country/Sub-region

12. Latin America Cryptococcosis Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Treatment Type, 2017–2027

        12.2.1. Amphotericin B 

            12.2.1.1. Amphocin 

            12.2.1.2. Fungizone

            12.2.1.3. Other

        12.2.2. Flucytosine 

            12.2.2.1. Ancobon 

            12.2.2.2. Other

        12.2.3. Fluconazole

            12.2.3.1. Diflucan

            12.2.3.2. Other

        12.2.4. Others (Voriconazole, Surgery Treatment, etc.)

    12.3. Market Value Forecast, by Distribution Channel, 2017–2027

        12.3.1. Hospital Pharmacies

        12.3.2. Retail Pharmacies

        12.3.3. Drug Store

        12.3.4. Mail Order Pharmacies

        12.3.5. Others

    12.4. Market Value Forecast, by Country/Sub-region, 2017–2027

        12.4.1. Brazil

        12.4.2. Mexico

        12.4.3. Rest of Latin America

    12.5. Market Attractiveness Analysis 

        12.5.1. By Treatment Type 

        12.5.2. By Distribution Channel 

        12.5.3. By Country/Sub-region

13. Middle East & Africa Cryptococcosis Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Treatment Type, 2017–2027

        13.2.1. Amphotericin B 

            13.2.1.1. Amphocin 

            13.2.1.2. Fungizone

            13.2.1.3. Other

        13.2.2. Flucytosine 

            13.2.2.1. Ancobon 

            13.2.2.2. Other

        13.2.3. Fluconazole

            13.2.3.1. Diflucan

            13.2.3.2. Other

        13.2.4. Others (Voriconazole, Surgery Treatment, etc.)

    13.3. Market Value Forecast, by Distribution Channel, 2017–2027

        13.3.1. Hospital Pharmacies

        13.3.2. Retail Pharmacies

        13.3.3. Drug Store

        13.3.4. Mail Order Pharmacies

        13.3.5. Others

    13.4. Market Value Forecast, by Country/Sub-region, 2017–2027

        13.4.1. GCC Countries

        13.4.2. South Africa

        13.4.3. Rest of Middle East & Africa

    13.5. Market Attractiveness Analysis 

        13.5.1. By Treatment Type 

        13.5.2. By Distribution Channel 

        13.5.3. By Country/Sub-region

14. Competition Landscape

    14.1. Market Player - Competition Matrix (By Tier and Size of companies)

    14.2. Market Share/Position Analysis, by Company, 2018

    14.3. Company Profiles

        14.3.1. Bristol-Myers Squibb Company

            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.1.2. Growth Strategies

            14.3.1.3. SWOT Analysis

        14.3.2. Janssen Biotech, Inc. (Johnson & Johnson)

            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.2.2. Growth Strategies

            14.3.2.3. SWOT Analysis

        14.3.3. Abbott Laboratories

            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.3.2. Growth Strategies

            14.3.3.3. SWOT Analysis

        14.3.4. Novartis AG

            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.4.2. Growth Strategies

            14.3.4.3. SWOT Analysis

        14.3.5. Pfizer, Inc.

            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.5.2. Growth Strategies

            14.3.5.3. SWOT Analysis

        14.3.6. Valeant Pharmaceuticals, Inc. 

            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.6.2. Growth Strategies

            14.3.6.3. SWOT Analysis

        14.3.7. Glenmark Pharmaceuticals 

            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.7.2. Growth Strategies

            14.3.7.3. SWOT Analysis

        14.3.8. Viamet Pharmaceuticals, Inc.  

            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.8.2. Growth Strategies

            14.3.8.3. SWOT Analysis

        14.3.9. Sigmapharm Laboratories LLC  

            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            14.3.9.2. Growth Strategies

            14.3.9.3. SWOT Analysis

List of Tables

TABLE 1 Overview of major clinical trials for Cryptococcosis Treatment

TABLE 2 Global Cryptococcosis Market Size (US$ Mn) Forecast, by Treatment, 2014–2024

TABLE 3 Global Cryptococcosis Market Size (US$ Mn) Forecast, by Amphotericin B Treatment, 2014–2024

TABLE 4 Global Cryptococcosis Market Size (US$ Mn) Forecast, by Flucytosine Treatment, 2014–2024

TABLE 5 Global Cryptococcosis Market Size (US$ Mn) Forecast, by Fluconazole Treatment, 2014–2024

TABLE 6 Global Cryptococcosis Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024

TABLE 7 Global Cryptococcosis Market Size (US$ Mn) Forecast, by Region, 2014–2024

TABLE 8 North America Cryptococcosis Market Size (US$ Mn) Forecast, by Country, 2014–2024

TABLE 9 North America Cryptococcosis Market Size (US$ Mn) Forecast, by Treatment, 2014–2024

TABLE 10 North America Cryptococcosis Market Size (US$ Mn) Forecast, by Amphotericin B Treatment, 2014–2024

TABLE 11 North America Cryptococcosis Market Size (US$ Mn) Forecast, by Flucytosine Treatment, 2014–2024

TABLE 12 North America Cryptococcosis Market Size (US$ Mn) Forecast, by Fluconazole Treatment, 2014–2024

TABLE 13 North America Cryptococcosis Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024

TABLE 14 Middle East & Africa Cryptococcosis Market Size (US$ Mn) Forecast, by Country/Region, 2014–2024

TABLE 15 Middle East & Africa Cryptococcosis Market Size (US$ Mn) Forecast, by Treatment, 2014–2024

TABLE 16 Middle East & Africa Cryptococcosis Market Size (US$ Mn) Forecast, by Amphotericin B Treatment, 2014–2024

TABLE 17 Middle East & Africa Cryptococcosis Market Size (US$ Mn) Forecast, by Flucytosine Treatment, 2014–2024

TABLE 18 Middle East & Africa Cryptococcosis Market Size (US$ Mn) Forecast, by Fluconazole Treatment, 2014–2024

TABLE 19 Middle East & Africa Cryptococcosis Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024

TABLE 20 Asia Pacific Cryptococcosis Market Size (US$ Mn) Forecast, by Country/Region, 2014–2024

TABLE 21 Asia Pacific Cryptococcosis Market Size (US$ Mn) Forecast, by Treatment, 2014–2024

TABLE 22 Asia Pacific Cryptococcosis Market Size (US$ Mn) Forecast, by Amphotericin B Treatment, 2014–2024

TABLE 23 Asia Pacific Cryptococcosis Market Size (US$ Mn) Forecast, by Flucytosine Treatment, 2014–2024

TABLE 24 Asia Pacific Cryptococcosis Market Size (US$ Mn) Forecast, by Fluconazole Treatment, 2014–2024

TABLE 25 Asia Pacific Cryptococcosis Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024

TABLE 26 Europe Cryptococcosis Market Size (US$ Mn) Forecast, by Country/Region, 2014–2024

TABLE 27 Europe Cryptococcosis Market Size (US$ Mn) Forecast, by Treatment, 2014–2024

TABLE 28 Europe Cryptococcosis Market Size (US$ Mn) Forecast, by Amphotericin B Treatment, 2014–2024

TABLE 29 Europe Cryptococcosis Market Size (US$ Mn) Forecast, by Flucytosine Treatment, 2014–2024

TABLE 30 Europe Cryptococcosis Market Size (US$ Mn) Forecast, by Fluconazole Treatment, 2014–2024

TABLE 31 Europe Cryptococcosis Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024

TABLE 32 Latin America Cryptococcosis Market Size (US$ Mn) Forecast, by Country, 2014–2024

TABLE 33 Latin America Cryptococcosis Market Size (US$ Mn) Forecast, by Treatment, 2014–2024

TABLE 34 Latin America Cryptococcosis Market Size (US$ Mn) Forecast, by Amphotericin B (Treatment), 2014–2024

TABLE 35 Latin America Cryptococcosis Market Size (US$ Mn) Forecast, by Flucytosine (Treatment), 2014–2024

TABLE 36 Latin America Cryptococcosis Market Size (US$ Mn) Forecast, by Fluconazole (Treatment), 2014–2024

TABLE 37 Latin America Cryptococcosis Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024

List of Figures

Figure 01 - Global Cryptococcosis Market Size (US$ Mn) Forecast, 2017–2027

Figure 02 - Market Value Share By Region (2016)

Figure 03 - Market Value Share By Treatment (2016)

Figure 04 -  Market Value Share By Distribution Channel (2016)

Figure 05 - Global Cryptococcosis Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 06 - Global Cryptococcosis Market - Amphotericin B Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

Figure 07 - Global Cryptococcosis Market - Flucytosine Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

Figure 08 - Global Cryptococcosis Market - Fluconazole Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

Figure 09 - Global Cryptococcosis Market - Others Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2027

Figure 10 - Cryptococcosis Market Attractiveness Analysis, by Treatment, 2019–2027

Figure 11 - Global Cryptococcosis Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 12 - Global Cryptococcosis Market - Hospital Pharmacies Revenue and Y-o-Y Growth (%), 2017–2027

Figure 13 -  Global Cryptococcosis Market - Retail Pharmacies Revenue and Y-o-Y Growth (%), 2017–2027

Figure 14 - Global Cryptococcosis Market - Drug Store Revenue and Y-o-Y Growth (%), 2017–2027

Figure 15 - Global Cryptococcosis Market - Mail Order Pharmacies Revenue and Y-o-Y Growth (%), 2017–2027

Figure 16 - Global Cryptococcosis Market - Other Distribution Channels Revenue and Y-o-Y Growth (%), 2017–2027

Figure 17 - Global Cryptococcosis Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 18 - Global Cryptococcosis Market Value Share Analysis, by Region, 2018 and 2027

Figure 19 - Global Cryptococcosis Market Attractiveness Analysis, by Region, 2017–2027

Figure 20 - North America Cryptococcosis Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2027

Figure 21 - North America Cryptococcosis Market Attractiveness Analysis, by Country, 2019–2027

Figure 22 - North America Cryptococcosis Market Value Share Analysis, by Country, 2018 and 2027

Figure 23 - North America Cryptococcosis Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 24 - North America Cryptococcosis Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 25 - North America Market Attractiveness Analysis, by Treatment, 2017–2027

Figure 26 - North America Market Attractiveness Analysis, by Distribution Channel, 2017–2027

Figure 27 - Middle East & Africa Cryptococcosis Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2027

Figure 28 - Middle East & Africa Cryptococcosis Market Attractiveness Analysis, by Country/Region, 2019–2027

Figure 29 - Middle East & Africa Cryptococcosis Market Value Share Analysis, by Country/Region, 2018 and 2027

Figure 30 - Middle East & Africa Cryptococcosis Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 31 - Middle East & Africa Cryptococcosis Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 32 - Middle East & Africa Market Attractiveness Analysis, by Treatment, 2017–2027

Figure 33 - Middle East & Africa Market Attractiveness Analysis, by Distribution Channel, 2017–2027

Figure 34 - Asia Pacific Cryptococcosis Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2027

Figure 35 - Asia Pacific Cryptococcosis Market Attractiveness Analysis, by Country/Region, 2019–2027

Figure 36 - Asia Pacific Cryptococcosis Market Value Share Analysis, by Country/Region, 2018 and 2027

Figure 37 - Asia Pacific Cryptococcosis Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 38 - Asia Pacific Cryptococcosis Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 39 - Asia Pacific Market Attractiveness Analysis, by Treatment, 2019–2027

Figure 40 - Asia Pacific Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 41 - Europe Cryptococcosis Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2027

Figure 42 - Europe Cryptococcosis Market Attractiveness Analysis, by Country/Region, 2019–2027

Figure 43 - Europe Cryptococcosis Market Value Share Analysis, by Country/Region, 2018 and 2027

Figure 44 - Europe Cryptococcosis Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 45 - Europe Cryptococcosis Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 46 - Europe Market Attractiveness Analysis, by Treatment, 2017–2027

Figure 47 - Europe Market Attractiveness Analysis, by Distribution Channel, 2017–2027

Figure 48 - Latin America Cryptococcosis Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2027

Figure 49 - Latin America Cryptococcosis Market Attractiveness Analysis, by Country, 2019–2027

Figure 50 - Latin America Cryptococcosis Market Value Share Analysis, by Country, 2018 and 2027

Figure 51 - Latin America Cryptococcosis Market Value Share Analysis, by Treatment, 2018 and 2027

Figure 52 - Latin America Cryptococcosis Market Value Share Analysis, by Distribution Channel, 2018 and 2027

Figure 53 - Latin America Market Attractiveness Analysis, by Treatment, 2019–2027

Figure 54 - Latin America Market Attractiveness Analysis, by Distribution Channel, 2019–2027

Figure 55 - Global Cryptococcosis Market Share Analysis, by Company, 2018 (Estimated)

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

725

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved